Feedback / Questions
GV20-0251 - GV20 Therap
https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-updated-phase-1-monotherapy-data-on-gv20-0251-at-the-asco-annual-meeting-2025-302463359.html
Jun 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next